Selective inhibition of polyglutamine protein expression
US9574191B2 · kind B2 · utility
6Cited by
1References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 3, 2011 |
| Grant date | Feb 21, 2017 |
| Priority date | — |
| Expiry date | Nov 14, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/34
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the selective inhibition of protein expression of CAG repeat-related disease proteins such as Huntingtin Disease Protein and Ataxin-3 using double-stranded RNAs and nucleic acid analogs. Chemically-modified RNAs having at least one mismatch as compared to the target CAG repeat sequence are specifically contemplated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.